NLTX vs. VNDA, CRMD, ORGO, KMDA, URGN, VRCA, VTYX, PROC, AQST, and AVIR
Should you be buying Neoleukin Therapeutics stock or one of its competitors? The main competitors of Neoleukin Therapeutics include Vanda Pharmaceuticals (VNDA), CorMedix (CRMD), Organogenesis (ORGO), Kamada (KMDA), UroGen Pharma (URGN), Verrica Pharmaceuticals (VRCA), Ventyx Biosciences (VTYX), Procaps Group (PROC), Aquestive Therapeutics (AQST), and Atea Pharmaceuticals (AVIR). These companies are all part of the "pharmaceutical preparations" industry.
Neoleukin Therapeutics (NASDAQ:NLTX) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, community ranking, profitability, media sentiment, earnings, risk and valuation.
Vanda Pharmaceuticals received 484 more outperform votes than Neoleukin Therapeutics when rated by MarketBeat users. Likewise, 68.55% of users gave Vanda Pharmaceuticals an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote.
Vanda Pharmaceuticals has higher revenue and earnings than Neoleukin Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Neoleukin Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Vanda Pharmaceuticals has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500.
Vanda Pharmaceuticals has a net margin of 1.30% compared to Neoleukin Therapeutics' net margin of 0.00%. Vanda Pharmaceuticals' return on equity of 0.46% beat Neoleukin Therapeutics' return on equity.
In the previous week, Vanda Pharmaceuticals had 14 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 14 mentions for Vanda Pharmaceuticals and 0 mentions for Neoleukin Therapeutics. Vanda Pharmaceuticals' average media sentiment score of 0.08 beat Neoleukin Therapeutics' score of 0.00 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media.
52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by company insiders. Comparatively, 7.7% of Vanda Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Vanda Pharmaceuticals beats Neoleukin Therapeutics on 13 of the 14 factors compared between the two stocks.
Get Neoleukin Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NLTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neoleukin Therapeutics Competitors List
Related Companies and Tools
